Rapamycin Expands and Confers Resistance to Apoptosis of Human Inducible Regulatory T Cells (TRI)

Abstract

The immunosuppressive drug Rapamycin (RAPA) has been shown to promote expansion of CD4⁺IL-10⁺ natural human regulatory T cells (nTreg) in vitro and in vivo. RAPA effects on inducible Treg (Tri) are unknown, and this study explores in vitro responses of Tr1 to this drug. CD4⁺CD25^neg T cells isolated from PBMC of normal donors were used to generate Tr1 cells. Expanded Tr1 cells were tested for surface markers, expression of survival proteins, resistance to apoptosis and the ability to suppress proliferation of autologous CD4⁺CD25^neg responder T cells (RC) in functional assays. RAPA was found to promote the generation of human Tr1 cells from autologous CD4⁺CD2S^neg precursors in peripheral blood. Tr1 cells + RAPA mediated higher suppression (p<0.01) of RC proliferation than Tr1 cells cultured without RAPA. Tr1 cells + RAPA also expressed higher levels of FasL and granzyme B (p<0.002), produced more IL-10 and TGF-βl and were more resistant to activation-induced cell death (p<0.02). RAPA up-regulated expression of the Bcl-2 family anti-apoptotic proteins in Tri. In addition, stimulation of Tr1 by LPS + RAPA resulted in increased proliferation and resistance to apoptosis. RAPA favors in vitro generation of inducible human Treg (Tr1) from CD4⁺CD25^neg precursor cells and significantly enhances their survival and suppressor functions.

Keywords

inducible regulatory T cells Tr1 apoptosis IL-10

References

Roncarolo

Gregori

Battaglia

Bacchetta

Fleischhauer

Levings

. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006; 212:28–50.

Battaglia

Stabilini

Roncarolo

. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005; 105:4743–48.

Battaglia

Stabilini

Migliavacca

Horejs-Hoeck

Kaupper

Roncarolo

. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006; 177:8338–47.

Bergmann

Strauss

Wang

Szczepanski

Lang

Johnson

Whiteside

. T regulatory type 1 cells in squamous cell carcinoma of the head and neck: Mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 2008; 14:3706–15.

Sempere

Soriano

Benito

. T regulatory cells and HIV infection. AIDS Rev 2007; 9:54–60.

Bergmann

Strauss

Zeidler

Lang

Whiteside

. Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment. Cancer Immunol Immunother 2007; 56:1429–42.

Cao

Cai

Fehniger

Song

Collins

Piwnica-Worms

Ley

. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 2007; 27:635–46.

Mandapathil

Hilldorfer

Szczepanski

. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem 2010; 285:7176–86.

Roncarolo

Battaglia

. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol 2007; 7:585–98.

10.

Trzonkowski

Szarynska

Mysliwska

Mysliwski

. Ex vivo expansion of CD4(+)CD25(+)T regulatory cells for immunosuppressive therapy. Cytometry A 2009; 75:175–88.

11.

Brunstein

Miller

Cao

. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: Safety profile and detection kinetics. Blood 2011; 117:1061–70.

12.

Ziegler

. FOXP3: Not just for regulatory T cells anymore. Eur J Immunol 2007; 37:21–23

13.

Mandapathil

Lang

Gorelik

Whiteside

. Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. J Immunol Methods 2009; 346:55–63.

14.

Seddiki

Santner-Nanan

Martinson

. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006; 203:1693–700.

15.

Schuler

Harasymczuk

Schilling

Lang

Whiteside

. Separation of human CD4+CD39+ T cells by magnetic beads reveals two phenotypically and functionally different subsets. J Immunol Meth 2011; 369:59–68.

16.

Theofllopoulos

Dummer

Kono

. T cell homeostasis and systemic autoimmunity. J Clin Invest 2001; 108:335–40.

17.

Peters

Koenen

Hilbrands

Joosten

. Immunotherapy with regulatory T cells in transplantation. Immunotherapy 2009; 1:855–71.

18.

Battaglia

Stabilini

Draghici

Gregori

Mocchetti

Bonifacio

Roncarolo

. Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes 2006; 55:40–49.

19.

Strauss

Czystowska

Szajnik

Mandapathil

Whiteside

. Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PLoS One 2009; 4:e5994.

20.

Zeiser

Leveson-Gower

Zambricki

Kambham

Beilhack

Loh

Hou

Negrin

. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 2008; 111:453–62.

21.

Thomson

Turnquist

Raimondi

. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009; 9:324–37.

22.

Mandapathil

Szczepanski

Szajnik

Ren

Jackson

Johnson

Gorelik

Lang

Whiteside

. Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem 2010; 285(36):27571–80.

23.

Czystowska

Strauss

Bergmann

Szajnik

Rabinowich

Whiteside

. Reciprocal granzyme/perforin-mediated death of human regulatory and responder T cells is regulated by interleukin-2 (IL-2). J Mol Med 2010; 88:577–88.

24.

Taylor

Watson

Bradley

. Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol 2005; 56:23–46.

25.

Meier-Kriesche

Steffen

Chu

Loveland

Gordon

Morris

Kaplan

. Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival. Am J Transplant 2004; 4:2058–66.

26.

Chapman

O'Connell

Nankivell

. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005; 16:3015–26.

27.

Geissler

Schlitt

. The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation. Kidney Int 2010; 78:1075–79.

28.

Zheng

Sanchez-Fueyo

Sho

Domenig

Sayegh

Strom

. Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity 2003; 19:503–14.

29.

Sakaguchi

Miyara

Costantino

Hafler

. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010; 10:490–500.

30.

Young

. Epidemiology and management of infectious complications of contemporary management of chronic leukemias. Infect Disord Drug Targets 2011; 11:3–10.

31.

Allan

Broady

Gregori

Himmel

Locke

Roncarolo

Bacchetta

Levings

. CD4+ T-regulatory cells: Toward therapy for human diseases. Immunol Rev 2008; 223:391–421.

32.

Grossman

Verbsky

Barchet

Colonna

Atkinson

Ley

. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 2004; 21:589–601.

33.

Strauss

Bergmann

Whiteside

. Human circulating CD4+CD25highFoxp3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis. J Immunol 2009; 182:1469–80.

34.

Passerini

Di Nunzio

Gregori

. Functional type 1 regulatory T cells develop regardless of FOXP3 mutations in patients with IPEX syndrome. Eur J Immunol 2011; 41:1120–31.

35.

Leveson-Gower

Olson

Sega

Luong

Baker

Zeiser

Negrin

. Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4 dependent mechanism. Blood 2011; 117:3220–29.